

Incidental Discovery of Dedifferentiated Liposarcoma of the Anterior Mediastinum: A Case Report

Knauss HM¹, Glosser LD¹, Shi SX^{2*} and Taleb M³

¹Department of Medical Education, University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA

²Clinical Neuroscience Research Center, Department of Neurosurgery and Neurology, Tulane University School of Medicine, New Orleans, LA, USA

³Department of Pulmonary/Critical Care Medicine, University of Toledo Medical Center, Toledo, OH, USA

*Corresponding author: Shi SX, Clinical Neuroscience Research Center, Department of Neurosurgery and Neurology, Tulane University School of Medicine, New Orleans, LA, USA



ARTICLE INFO

Received: 📅 August 30, 2021

Published: 📅 September 07, 2021

Citation: Knauss HM, Glosser LD, Shi SX, Taleb M. Incidental Discovery of Dedifferentiated Liposarcoma of the Anterior Mediastinum: A Case Report. Biomed J Sci & Tech Res 38(4)-2021. BJSTR. MS.ID.006178.

ABSTRACT

Liposarcomas of the mediastinum are uncommon, and those of the anterior compartment are even more rare. The majority of cases are symptomatic on presentation due to mass effect. We report the case of a large asymptomatic anterior mediastinal liposarcoma discovered incidentally during workup for intraparenchymal hemorrhage.

Keywords: Mediastinum; Liposarcoma; Incidental; Intraparenchymal Hemorrhage

Introduction

Liposarcomas are common soft-tissue neoplasms accounting for 20% of mesenchymal malignancies [1]. Mediastinal occurrence is rare, accounting for only 2% of all liposarcomas and less than 1% of mediastinal tumors [2,3]. 85% of mediastinal liposarcomas present with mass effect symptoms, such as shortness of breath, arrhythmias, and hoarseness [4]. Only 15% of mediastinal liposarcomas are discovered incidentally [4]. We present a case of an 83 year old male who initially presented to the emergency department with intraparenchymal hemorrhage, incidentally found to have a 13.2 cm x 6.3 cm dedifferentiated liposarcoma of the anterior mediastinum and multiple pulmonary nodules without symptoms of mass effect.

Case Report

An 83-year-old male with a past medical history significant for prostate cancer status post radical prostatectomy, remote 20 pack

year smoking history (quit 40 years ago), dyslipidemia, and atrial fibrillation (on Eliquis) presented to the emergency department with a 4-day history of persistent severe occipital headache. The headache was worse in the mornings and accompanied by vomitus, composed mostly of phlegm. In the emergency department, the patient also presented with right homonymous hemianopsia. CT angiography of the head and neck demonstrated left occipital intraparenchymal hemorrhage with incidental findings of a mass in the anterior-superior mediastinum and small pulmonary nodules in the left upper lobe (Figure 1). CT chest with contrast showed a 13.2 x 6.3 cm anterior mediastinal mass with both fatty and soft tissue components (Figure 2). Multiple pulmonary nodules consistent with metastases were identified in the left upper lobe, left lower lobe, right upper lobe, and right middle lobe. The mediastinal mass was not associated with shortness of breath, hoarseness, or other symptoms of mass effect. Given the chest CT findings, brain MRI

with and without contrast was performed to assess for intracranial masses. MRI showed stable left occipital hematoma and multiple old punctate parenchymal hemorrhages without evidence of other intracranial pathology.

The patient was medically managed for the intraparenchymal hemorrhage without complication. On hospital day 3, the patient underwent CT-guided biopsy of the 13.2 x 6.3 cm mediastinal mass. Pathology revealed dedifferentiated liposarcoma of at least intermediate grade with myoid differentiation. Tumor cells stained positive for CD34, CD56, desmin, CD99, vimentin, and scanty positive for S100. FISH analysis confirmed MDM2 gene amplification. The patient was discharged home with outpatient

follow-up with pulmonary medicine and hematology/oncology. Tumor staging with PET-CT from skull to thigh showed abnormal fluorodeoxyglucose (FDG) activity in an anterior mediastinal mass at the right side of the level of the ascending aorta, a separate anterior mediastinal soft tissue mass near midline consistent with malignant mediastinal adenopathy, a pulmonary nodule in the anterior right lung, and a small right hilar lymph node (Table 1). The patient was evaluated by cardiothoracic surgery but was not deemed an appropriate candidate for surgical resection of the mass. He was referred to radiation oncology, and decision was made to palliatively radiate the mass with future consideration for systemic therapy.




Figure 1: CTA of neck initially performed to evaluate intracranial hemorrhage incidentally discovers soft tissue mass of anterior superior mediastinum on the most inferior view.




Figure 2: CT chest with contrast. Large 13.2 x 6.3 cm mass in the anterior mediastinum identified on transverse (A) and sagittal (B) view. (C) Right upper lobe pulmonary nodule identified along the minor fissure.

Table 1: Size and standard uptake values (SUV) of areas with abnormal fluorodeoxyglucose (FDG) activity identified on PET-CT.

Mass description	Size (cm)	Standard uptake value (SUV) max
Right anterior mediastinum	3.9 x 3.4	8.7
Midline-anterior mediastinal soft tissue	3	8.1
Right hilar lymph node	1.2	2.8
Pulmonary nodule-anterior right lung	1.0 x 0.6	1.3

Discussion

Liposarcomas arise from adipocytic differentiation and are classified by four histological subtypes: myxoid, pleomorphic, well-differentiated, and de-differentiated [5]. De-differentiated liposarcomas (DDLs) comprise 15-20% of all liposarcomas and typically follow an aggressive course with poor response to therapy [5]. DDLs arise from primary origin in 80-90% of cases, with 10% arising from secondary dedifferentiation of well-differentiated liposarcomas (WDLs) [6]. DDLs most commonly occurs in the retroperitoneum or extremities, and rarely in the anterior mediastinum [3]. Regardless of location, the prognosis of DDLs is poor. A retrospective evaluation reported overall survival rates at 5 and 10 years is 57.2% and 40.1% respectively [7]. Prognostic factors include tumor size, grade, histology, metastases, and margin status after resection [7,8]. Mediastinal liposarcomas present with symptoms in 85% of cases, often related to compression of intrathoracic structures [4]. The most frequently reported symptoms are dyspnea, chest pain, and tachypnea [9]. Other symptoms may include dysphagia, wheezing, arrhythmias, heart failure, and superior vena cava syndrome [4,9]. Our case is unique as it was asymptomatic and found incidentally during work up for intraparenchymal hemorrhage.

Current treatment guidelines for dedifferentiated mediastinal liposarcomas recommend surgical intervention [10]. Complete resection with negative margins is preferred, although positive margins may be left if the tumor invades critical structures [10]. Multiple operations may be necessary if positive margins remain [10]. However, these guidelines are limited due to a small number of cases documented. A retrospective review from 1950-2018 of primary mediastinal dedifferentiated liposarcoma found 39 cases, of which 34 were treated with surgical resection, 2 with chemotherapy, and 3 unknown [11]. Another review from 2002-2016 found 19 cases of mediastinal dedifferentiated liposarcoma, of which 17 were treated with surgical resection, 1 with chemotherapy, and 1 unknown [12]. In these studies, only 1 patient treated without surgical resection had documented outcomes.

This patient underwent chemotherapy with doxorubicin due to advanced inoperable disease and died less than 1 month after diagnosis [12].

Alternative systemic therapies are available when surgical intervention is not possible. However, due to the rarity of occurrence, long-term prognostic data of dedifferentiated mediastinal liposarcoma is limited to few case series and small retrospective reviews. DDLs has poor sensitivity to chemotherapy. Anthracycline-based therapy is the first line, either as monotherapy or in combination with ifosfamide [13,14]. Response rates to systemic therapy are reported to be 12% in WDLs/DDLS, with median overall survival of 15 months [13]. Novel targeted-therapies are emerging with inhibitors of CDK4/6, MDM2, Exportin-1, PI3K, mTOR, and tyrosine kinase [13,14]. The role for these therapies remains under investigation. We present a rare case of a large dedifferentiated liposarcoma located in the anterior mediastinum, found incidentally during workup for intraparenchymal hemorrhage. Although liposarcomas rarely occur in the mediastinum, clinicians should consider this diagnosis on the differential for soft tissue masses of the mediastinum. Importantly, most cases present with symptoms related to compression of intrathoracic structures, although our case was asymptomatic. Surgical resection is the preferred treatment for dedifferentiated liposarcomas, however treatment guidelines for inoperable cases are not well-defined. This case demonstrates the difficulty in diagnosis for dedifferentiated liposarcomas with silent presentation and calls for further study to determine the role of non-surgical interventions.

Acknowledgement

None.

Conflict of Interest Disclosure

None declared.

Ethics Approval Statement

Informed consent was obtained from the patient for the publication of this case report and accompanying images.

CRedit Author Contribution Statement

Hanna M. Knauss: Writing – Original Draft, Writing – Review & Editing, Project administration. Logan D. Glosser: Writing – Review & editing, Investigation, Visualization. Samuel Shi: Writing – Review & editing. Dr. Mohammed Taleb: Conceptualization, Supervision

All authors read and approved the final version to be published.

References

1. Thway K (2019) Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review. *Semin Diagn Pathol* 36(2): 112-121.

2. Krishnasamy S, Krishna Nair A, Hashim SA, Raja Mokhtar RA (2019) Mediastinal liposarcoma: a rare visceral mediastinal tumour. *Interact Cardiovasc Thorac Surg* 29(6): 976-977.
3. Fernandez-Tena A, Lopez-Gonzalez FJ (2017) Mediastinal liposarcoma in a 30-year-old woman with dyspnea and chest pain. *Respir Med Case Rep* 21: 86-88.
4. Nguyen DC, Olatubosun O, Yu W, Loor G, Burt BM (2018) Giant Mediastinal Liposarcoma: A Rare Yet Distinct Clinical Entity. *Ann Thorac Surg* 106(3): e117-e119.
5. Lee ATJ, Thway K, Huang PH, Jones RL (2018) Clinical and Molecular Spectrum of Liposarcoma. *J Clin Oncol* 36(2): 151-159.
6. Wang XL, Gong JY, Xue Y (2021) Obvious Reduction of the Tumor Size in Dedifferentiated Liposarcoma in a Lung Metastasis Patient Receiving Individualized Treatment. *Case Rep Oncol* 14(2): 1080-1084.
7. Knebel C, Lenze U, Pohlig F, Lenze F, Harrasser N, et al. (2017) Prognostic factors and outcome of Liposarcoma patients: a retrospective evaluation over 15 years. *BMC Cancer* 17(1): 410.
8. Kim HS, Lee J, Yi SY, Jun HJ, Choi YL, et al. (2009) Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. *BMC Cancer* 9: 205.
9. Barbetakis N, Samanidis G, Samanidou E, Kirodimos E, Kiziridou A, et al. (2007) Primary mediastinal liposarcoma: a case report. *J Med Case Rep* 1: 161.
10. Soeroso NN, Pradana A, Djaka M, Ayudika M, Ngadimin S, et al. (2018) An unusual case of recurrent huge primary mediastinal dedifferentiated liposarcoma. *Int J Surg Case Rep* 50: 140-143.
11. Chen HG, Zhang K, Wu WB, Wu YH, Zhang J, et al. (2020) Combining surgery with (125)I brachytherapy for recurrent mediastinal dedifferentiated liposarcoma: A case report and review of literature. *World J Clin Cases* 8(5): 939-945.
12. Miura K, Hamanaka K, Matsuoka S, Takeda T, Agatsuma H, et al. (2018) Primary mediastinal dedifferentiated liposarcoma: Five case reports and a review. *Thorac Cancer* 9(12): 1733-1740.
13. McGovern Y, Zhou CD, Jones RL (2017) Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. *Front Oncol* 7: 292.
14. Haddox CL, Riedel RF (2021) Recent advances in the understanding and management of liposarcoma. *Fac Rev* 10: 1.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2021.38.006178

Shi SX. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>